CD52 (HI186) Antibody sc-51560 from Santa Cruz Biotechnology, Inc.

Published Figures

Register or Sign In to View Figures.

Leukemia
February 01 2023

Fig 1: Longitudinal scRNA-seq analyses for the identification of cellular and molecular reprogramming induced by chemotherapy in AML patients.A Left: t-SNE visualization of scRNA-seq data of primary refractory patient Pt#3 before and after chemotherapy. Right: Sankey plot showing the dynamic changes of cellular states after chemotherapy in Pt#3. B Left: t-SNE visualization of scRNA-seq data of primary refractory patient Pt#9 before and after chemotherapy. Right: Sankey plot showing the dynamic changes of cellular states after chemotherapy in Pt#9. C Left: t-SNE visualization of scRNA-seq data of Pt#10 who achieved partial remission. Right: Sankey plot showing the dynamic changes of cellular states after chemotherapy in Pt#10. D Sankey plot showing the dynamic changes of cellular states during chemotherapy in samples from the study of Galen et al. E Heatmap for differentially expressed genes after chemotherapy in Pt#3. F Principal component analysis (PCA) of the cellular states in Pt#3 based on the differentially expressed genes during chemotherapy. The dot shape represents the cellular states before or after chemotherapy. G, H Ridge plots showing the activity scores of transcriptional factors GATA2 and TAL1 in QSCs and PSPs during chemotherapy in Pt#3. I The enrichment of GATA2 and TAL1 peaks on gene CD52 based on the ChIP‐Seq data of K562 cell line.
Register or Sign In to View Figures.

Leukemia
February 01 2023

Fig 2: Validation of the enrichment of QSCs in refractory and early-relapsed AML patients by flow cytometry based on the markers identified by single-cell data.A Bar plots showing the percentage of each leukemia-like cellular state in CD99+ITGA4+ and CD99+ITGA4+CD52+LGALS1+ cells of single-cell transcriptomic data in this study. B Comparison of the percentage of CD99+CD49d+CD52+Galectin-1+ (QSCs) cells in viable CD45dimSSClow blasts among diagnosis (DX) sensitive patients, diagnosis (DX) resistant patients, and refractory/early-relapsed AML patients by flow cytometry. C Flow cytometric analysis of the percentage of QSCs in matched bone marrow samples from primary refractory AML patients (Pt#27, Pt#28, Pt#29, and Pt#30) before and after chemotherapy. D Comparison of the percentage of QSCs in viable CD45dimSSClow blasts at diagnosis and refractory bone marrow samples of Pt27, Pt#28, Pt#29, and Pt#30.
Register or Sign In to View Figures.

Leukemia
February 01 2023

Fig 3: Cell–cell communications between QSCs and monocytes by CD52-SIGLEC10 interaction.A Bubble chart showing the ligand-receptor interactions between QSCs/PSPs and monocytes in RR-AML patients. B Expression of CD52 (gray to red) and SIGLEC10 (gray to blue) on the pseudotime map of leukemia-like cells. C Bone marrow samples from AML patient Pt#11 and Pt#12 stained by anti-CD34 (green), anti-SIGLEC10 (red), anti-CD52 (purple) antibodies. DAPI (blue) is used for staining the live cells. Arrows depict the CD34+CD52+SIGLEC10+ QSCs. Scale bar, 20 µm. D Bone marrow samples from AML patient Pt#11 and Pt#12 stained by anti-CD14 (green), anti-SIGLEC10 (red), anti-CD52 (purple) antibodies. DAPI (blue) is used for staining the live cells. Arrows depict the CD14+CD52+SIGLEC10+ monocytes. Scale bar, 20 µm. E Multiplex IHC shows the interactions between CD34+CD52+ QSCs and CD14+SIGLEC10+ monocytes. F Relationship between CD52 expression levels and genomic events in TCGA AML cohort. Fisher exact test was used to measure the differences between groups. G, H Kaplan–Meier analysis of OS of TCGA AML patients. All patients were categorized into two groups based on the median level of CD52 (G) or SIGLEC10 (H) expression.

Be the first to write a review!

Citations:

(3)

Figures:

Supplier Page

Supplier Page from
Santa Cruz Biotechnology, Inc. for
CD52 (HI186) Antibody

Santa Cruz Biotechnology, Inc.'s CD52 (HI186) Antibody is a Mouse monoclonal antibody. The CD52 (HI186) Antibody was generated using CD52 as the antigen. It reacts with Homo Sapiens, and Human. This antibody has been shown to work in applications such as: Precipitation, Flow Cytometry, Immunofluorescence, Immunohistochemistry - fixed, Immunoprecipitation, and Western Blot.

Description

CD52 (HI186)

Leukemia

Leukemia

Leukemia

CD52 (HI186) Antibody from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (3)

Reviews

CD52 (HI186) Antibody from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map